{"id":"W2110901075","doi":"10.1186/2162-3619-3-26","title":"Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: a phase I/II randomized trial","year":2014,"lang":"en","type":"article","venue":"Experimental Hematology and Oncology","topic":"Growth Hormone and Insulin-like Growth Factors","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Merck","keywords":"Erlotinib; Medicine; Internal medicine; Randomized controlled trial; Oncology; Lung cancer; Antibody; Erlotinib Hydrochloride; Cancer; Immunology; Epidermal growth factor receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003261893,0.0002832779,0.001703185,0.0003675086,0.00008327306,0.000003891965,0.00007261088,0.0003069119,0.00001679509],"category_scores_gemma":[0.00006051217,0.0002114336,0.00006009253,0.0004281762,0.0003922283,0.0001207535,0.00004572885,0.0003731405,5.129211e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002081652,"about_ca_system_score_gemma":0.0003400352,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006456606,"about_ca_topic_score_gemma":0.0002604394,"domain_scores_codex":[0.9980481,0.0004608344,0.0005230808,0.0004405149,0.0001538596,0.0003735965],"domain_scores_gemma":[0.9989173,0.0003664139,0.0003500255,0.0001441586,0.0001180622,0.0001040718],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7260382,0.01205509,0.2388366,0.0001156961,0.0001438464,0.00003998445,0.003904921,0.000001694536,0.01813508,0.0003314697,0.00002466547,0.0003728018],"study_design_scores_gemma":[0.7981477,0.02118495,0.02916083,0.000122519,0.0001217997,0.00003549907,0.0002005713,0.001019123,0.1497741,0.00001806528,0.00001211219,0.0002027592],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9954258,0.0004310891,0.0001527929,0.00008641209,0.0001218717,0.003158722,0.000005349908,0.00002377539,0.0005941645],"genre_scores_gemma":[0.9991181,0.00003185109,0.0002447726,0.00009437132,0.00001972695,0.0003672816,0.00008404018,0.00002511096,0.00001475276],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2096757,"threshold_uncertainty_score":0.8622013,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.007392533454674619,"score_gpt":0.3067134082140757,"score_spread":0.2993208747594011,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}